Charles River’s Endotoxin Play

Oct 09 2012

Contract Pharma

In August 2012, Charles River Laboratories (CRL) acquired Accugenix for $17 million. The move is intended to boost CRL’s Endotoxin and Microbial Detection (EMD) portfolio of products and services. Announcing the deal, James C. Foster, CRL’s chairman, president and chief executive officer of Charles River, said, “The acquisition of Accugenix is the first step in our broader strategy to become the premier provider of rapid microbial and endotoxin detection products and services to the biopharmaceutical industry. Over the next several years, we intend to enhance our capabilities through both product extensions and acquisitions. We believe that execution of this strategy will advance our position as the market leader in endotoxin and microbial detection.”

Click here to learn more about the deal and the FDA’s approach to microbiology from Foster Jordan, corporate senior vice president of CRL’s Endotoxin and Microbial Detection business.